Skip to main content

14-08-2017 | Rheumatoid arthritis | News

News in brief

PRO results support baricitinib for RA patients

medwireNews: Secondary analyses of the RA-BEAM trial suggest that the clinical improvements experienced by rheumatoid arthritis (RA) patients treated with baricitinib are accompanied by corresponding gains in patient-reported outcomes (PROs).

PRO measures “may help address patient concerns such as how long it will take to feel improvement (onset of action), how long to try the new treatment before determining that it is not effective (efficacy plateau) and how long the treatment will be effective (sustainability or the risk of relapse),” say Edward Keystone (Mount Sinai Hospital, Toronto, Ontario, Canada) and study co-authors.

They found that the 487 participants treated with baricitinib 4 mg/day had significantly greater improvements in “most PROs across different domains of RA” at week 12 – including physical function, pain, and fatigue scores – compared with the 330 patients treated with adalimumab 40 mg every 2 weeks or the 488 in the placebo group. These PRO improvements were maintained at the 1-year follow-up.

The team also observed significant improvement in patient diary measures of morning joint stiffness duration and severity among those treated with baricitinib versus adalimumab or placebo.

“Collectively, the results of the present study demonstrate treatment benefits for baricitinib that appear clinically relevant,” write the researchers in the Annals of the Rheumatic Diseases.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

See also:

Related topics